GLP-1 Drugs

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Dosing errors in the medication semaglutide, prescribed as Wegovy and Ozempic, can cause severe or prolonged gastrointestinal issues that require medical attention

Researchers combined the drug harmine with a medication similar to Ozempic to boost the number and function of human insulin-producing cells transplanted into mice

Ozempic, Wegovy and other GLP-1 drugs are being investigated as treatments for many health conditions—from dementia to addiction to kidney problems

The neurons that produce a sick feeling and food aversion are distinct from those that induce a feeling of fullness

Blockbuster weight-loss drugs are revealing how appetite, pleasure and addiction work in the brain

As the patents on various weight-loss drugs near expiration, companies in India and China are vying to make lower-cost versions that will widen access to such treatments

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with type 2 diabetes

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off the drugs

The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works

A plethora of new weight-loss drugs are now available in the U.S., but they aren’t necessarily the same. Here’s a guide to the latest GLP-1 receptor agonists

Popular weight-loss and diabetes drugs, such as Ozempic and Wegovy, target metabolic pathways that gut microbes and food molecules already play a key role in regulating